Mode
Text Size
Log in / Sign up
Phase 2 N=353 Randomized Quadruple-blind Treatment

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

Diabetes Mellitus

Enrolled (actual)
353
Serious AEs
16.9%
Results posted
Dec 2010
Primary outcome: Primary: Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. — 1.016; 0.955; 0.874 mg/g

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Rosuvastatin (Drug); Atorvastatin (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
AstraZeneca
Primary completion
Mar 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.
1.016; 0.955; 0.874
SECONDARY
Urinary Protein/Creatinine Ratio at Week 26.
1.007; 0.994; 0.876
SECONDARY
Urinary Albumin/Creatinine Ratio at Week 26
0.927; 0.913; 0.831
SECONDARY
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
1.016; 0.836; 0.823
SECONDARY
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
-2.73; -5.46; -1.78
SECONDARY
Change From Baseline in eGFR at Week 52 [LOCF]
-3.70; -7.29; -1.61
SECONDARY
Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes
-0.03507; 0.14258; 0.01600
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC
0.07019; 0.26855; 0.12013
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]
-0.08588; 0.18570; -0.02491
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C
0.04510; 0.16280; 0.06739
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]
0.15614; 0.06987; 0.14226
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C
0.16111; 0.26194; 0.18918
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]
-0.12068; 0.15929; -0.05186
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C
0.02594; 0.24018; 0.07381
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]
-0.14569; 0.04948; -0.08471
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG
-0.05251; 0.11755; 0.01345
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
-0.05945; 0.12132; -0.02666
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
-0.05945; 0.12132; -0.02666
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
-0.02775; 0.06535; -0.01569
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
-0.02775; 0.06535; -0.01569
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
-0.06085; 0.12507; -0.02841
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
-0.06085; 0.12507; -0.02841
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]
0.15859; 0.13133; 0.15516
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1
0.16587; 0.18469; 0.18832
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]
-0.02276; 0.21405; 0.04578
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB
0.05397; 0.29486; 0.11079
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
0.00600; 0.22710; 0.03684
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
0.00600; 0.22710; 0.03684
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
0.13220; 0.35715; 0.18971
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
0.13220; 0.35715; 0.18971
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
0.10037; 0.21205; 0.12270
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
0.10037; 0.21205; 0.12270
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
0.14758; 0.26805; 0.17550
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
0.14758; 0.26805; 0.17550
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
0.09189; 0.33769; 0.14988
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
0.09189; 0.33769; 0.14988
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
-0.02947; 0.27198; 0.08787
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
-0.02947; 0.27198; 0.08787
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
0.01798; 0.20127; 0.05369
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
0.01798; 0.20127; 0.05369
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
0.03476; 0.10902; 0.04508
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
0.03476; 0.10902; 0.04508
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
0.01528; 0.21198; 0.05251
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
0.01528; 0.21198; 0.05251
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
0.16085; 0.15933; 0.17306
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
0.16085; 0.15933; 0.17306
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
0.10997; 0.30537; 0.15652
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
0.10997; 0.30537; 0.15652
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
0.04760; 0.25636; 0.07766
SECONDARY
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
0.04760; 0.25636; 0.07766
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
-0.13489; -0.18105; -0.14690
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
-0.13489; -0.18105; -0.14690
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
-0.11072; -0.12835; -0.11378
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
-0.11072; -0.12835; -0.11378
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
0.14457; -0.15546; 0.08841
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
0.14457; -0.15546; 0.08841
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
-0.17729; -0.19501; -0.17911
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
-0.17729; -0.19501; -0.17911
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
-0.24494; -0.07059; -0.15586
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
-0.24494; -0.07059; -0.15586
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
-0.26268; -0.08593; -0.23226
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
-0.26268; -0.08593; -0.23226
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
-0.19850; -0.06481; -0.17579
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
-0.19850; -0.06481; -0.17579
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
-0.26802; -0.11804; -0.24204
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
-0.26802; -0.11804; -0.24204
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
0.17909; 0.08090; 0.12787
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
0.17909; 0.08090; 0.12787
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
-0.15146; 0.04886; -0.12168
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
-0.15146; 0.04886; -0.12168
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
-0.26146; 0.05248; -0.22109
SECONDARY
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
-0.26146; 0.05248; -0.22109

Summary

The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and hypercholesterolaemia.

Eligibility Criteria

Inclusion Criteria

  • hyperlipidemia
  • urinary protein
  • diabetes

Exclusion Criteria

  • previous rosuvastatin treatment < 6 months prior to Visit 1
  • statin intolerance
  • severe hypertension
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00296374). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search